A clinical trial developed by a Taiwanese research team has offered a glimmer of hope for patients of neuroblastoma, a malignant cancer that appears in early childhood, a press statement released by the Academia Sinica said.
The research team at the research institute has proven that a combination of anti-cancer monoclonal antibodies (mAbs) with cytokines (natural hormones that help the immune system) is an effective anti-cancer therapy.
The new immunotherapy treatment pioneered by the research team, headed by Alice Yu (陳鈴津), deputy director of Academia Sinica’s Genomics Research Center, is the first study that confirms that immunotherapy is effective in improving cure rates for this childhood cancer, the statement said.
Yu, a pediatrician, has been working on the therapy for more than 20 years. She completed the Phase I and Phase II trials of this antibody at the University of California in San Diego.
The latest Phase III trial was sponsored by the US-based Children’s Oncology Group (COG), a cancer research organization, and the National Cancer Institute of the National Institutes of Health in the US. The latest results included children with neuroblastoma from many parts of the world.
Neuroblastoma is a malignant cancer occurring in early childhood in which the cancer cells arise from the nerve cells in the neck, chest or abdomen.
It is the most common cancer diagnosed in the first year of life and is responsible for 15 percent of cancer-related deaths in children.
The Phase III study showed that children with high risk neuroblastoma who received the new antibody-based immunotherapy (chimeric anti-GD2 antibody ch14.18) have a 20 percent better chance of living free of cancer, a significantly improved cure rate.
So far, Yu said, all US Federal Drug Administration (FDA) approved therapeutic anti-cancer mAbs or vaccines are directed against protein or glycoprotein antigens.
“The Phase III clinical trial is the first mAb targeting a glycolipid that has been shown to be effective,” Yu said.
More importantly, she added, this is the first study that proves that immunotherapy is effective in improving cure rates for this childhood cancer and her team is now focusing on making sure immunotherapy can be available to all children with this disease and on improving results.
COG Chairman Gregory Reaman stated in a press release that the clinical benefit of this approach against the notoriously stubborn child cancer is extraordinary and that the COG is anxious to continue its investigation to better define the toxicities and confirm its satisfactory risk-benefit ratio.
“We are hopeful that that this further study will result in commercialization and FDA approval and licensing of this experimental immunotherapeutic agent so that it can be made readily available as standard therapy to all children with this dreaded disease,” Reaman said in the statement.
Conventional treatment for the disease includes surgery, intensive chemotherapy with stem cell rescue (in which patients’ stem cells removed before treatment are returned after chemotherapy to repopulate the blood and immune system) and radiation therapy.
Despite these aggressive measures, only 30 percent of patients survive.
The immunotherapy evaluated in this study targets a specific glycolipid (sugar and fat) molecule on neuroblastoma cells called GD2 — which inhibits the immune system from attacking cancer cells — with an antibody called ch14.18.
This antibody binds to GD2 and provokes an attack by different types of immune cells against the cancer.
In her study, Yu and her colleagues compared the two-year event-free survival rate (the ratio of patients who were still alive and did not experience a recurrence) of 113 neuroblastoma patients who received the standard treatment (retinoic acid) plus the newly developed immunotherapy with 113 similar patients who only received the standard treatment.
The event-free survival rate for the immunotherapy group was 66 percent, compared to 46 percent for the standard treatment group. The most common side effects in the immunotherapy group were pain, vascular leak syndrome and allergic reactions.
As the study is the first effective immunotherapy reported for the disease and the first improvement on neuroblastoma cure rates of the last 10 years, it has drawn worldwide attention and was reported in USA Today and by US television network CBS.
It is estimated that it will take at least another two years to get FDA approval for the therapy.
Taiwan is to receive the first batch of Lockheed Martin F-16 Block 70 jets from the US late this month, a defense official said yesterday, after a year-long delay due to a logjam in US arms deliveries. Completing the NT$247.2 billion (US$7.69 billion) arms deal for 66 jets would make Taiwan the third nation in the world to receive factory-fresh advanced fighter jets of the same make and model, following Bahrain and Slovakia, the official said on condition of anonymity. F-16 Block 70/72 are newly manufactured F-16 jets built by Lockheed Martin to the standards of the F-16V upgrade package. Republic of China
Taiwan-Japan Travel Passes are available for use on public transit networks in the two countries, Taoyuan Metro Corp said yesterday, adding that discounts of up to 7 percent are available. Taoyuan Metro, the Taipei MRT and Japan’s Keisei Electric Railway teamed up to develop the pass. Taoyuan Metro operates the Taiwan Taoyuan International Airport MRT Line, while Keisei Electric Railway offers express services between Tokyo’s Narita Airport, and the Keisei Ueno and Nippori stations in the Japanese capital, as well as between Narita and Haneda airports. The basic package comprises one one-way ticket on the Taoyuan MRT Line and one Skyliner ticket on
Starlux Airlines, Taiwan’s newest international carrier, has announced it would apply to join the Oneworld global airline alliance before the end of next year. In an investor conference on Monday, Starlux Airlines chief executive officer Glenn Chai (翟健華) said joining the alliance would help it access Taiwan. Chai said that if accepted, Starlux would work with other airlines in the alliance on flight schedules, passenger transits and frequent flyer programs. The Oneworld alliance has 13 members, including American Airlines, British Airways, Cathay Pacific and Qantas, and serves more than 900 destinations in 170 territories. Joining Oneworld would also help boost
A new tropical storm formed late yesterday near Guam and is to approach closest to Taiwan on Thursday, the Central Weather Administration (CWA) said. Tropical Storm Pulasan became the 14th named storm of the year at 9:25pm yesterday, the agency said. As of 8am today, it was near Guam traveling northwest at 21kph, it said. The storm’s structure is relatively loose and conditions for strengthening are limited, WeatherRisk analyst Wu Sheng-yu (吳聖宇) said on Facebook. Its path is likely to be similar to Typhoon Bebinca, which passed north of Taiwan over Japan’s Ryukyu Islands and made landfall in Shanghai this morning, he said. However, it